These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30033656)

  • 21. Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts.
    Martin P; Cohen JB; Wang M; Kumar A; Hill B; Villa D; Switchenko JM; Kahl B; Maddocks K; Grover NS; Qi K; Parisi L; Daly K; Zhu A; Salles G
    J Clin Oncol; 2023 Jan; 41(3):541-554. PubMed ID: 35763708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.
    Rancea M; Monsef I; von Tresckow B; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2013 Jun; (6):CD009411. PubMed ID: 23784872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment patterns and outcomes of older patients with mantle cell lymphoma in an Asian population.
    Yang X; Khoo LP; Chang EWY; Yang VS; Poon E; Somasundaram N; Farid M; Tang TPL; Tao M; Lim ST; Chan JY
    BMC Cancer; 2021 May; 21(1):566. PubMed ID: 34001056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma.
    Schulz H; Bohlius J; Skoetz N; Trelle S; Kober T; Reiser M; Dreyling M; Herold M; Schwarzer G; Hallek M; Engert A
    Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD003805. PubMed ID: 17943799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrating monoclonal antibodies into the management of mantle cell lymphoma.
    Berinstein NL; Mangel J
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):2-6. PubMed ID: 15042527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Upfront autologous stem cell transplantation for untreated diffuse large B cell lymphoma patients in rituximab era: a systematic review and meta-analysis.
    Ma SY; Tian XP; Cai J; Zhong GZ; Chen X; Huang HQ; Lin TY; Li ZM; Cai QQ
    Ann Hematol; 2020 Jun; 99(6):1311-1319. PubMed ID: 32285160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma.
    Bouard L; Tessoulin B; Thieblemont C; Bouabdallah K; Gastinne T; Oberic L; Carras S; Delette C; Casasnovas O; Dartigeas C; Cacheux V; Masse S; Hermine O; Le Gouill S
    Haematologica; 2022 Sep; 107(9):2163-2172. PubMed ID: 35172560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?
    Kumar A
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):155-162. PubMed ID: 36485104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?
    Chaudhary L; Kharfan-Dabaja MA; Hari P; Hamadani M
    Bone Marrow Transplant; 2013 Nov; 48(12):1489-96. PubMed ID: 23584438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation.
    Metzner B; Müller TH; Gebauer W; Casper J; Kraemer D; Rosien B; Schumann-Binarsch S; Thole R; Köhne CH; Dreyling M; Hoster E; Pott C
    Ann Hematol; 2014 May; 93(5):803-10. PubMed ID: 24337447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
    William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?
    Epperla N; Fenske TS; Lazarus HM; Hamadani M
    Bone Marrow Transplant; 2015 Nov; 50(11):1393-404. PubMed ID: 26281033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis.
    Al Khabori M; de Almeida JR; Guyatt GH; Kuruvilla J; Crump M
    J Natl Cancer Inst; 2012 Jan; 104(1):18-28. PubMed ID: 22190633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clearing minimal residual disease with rituximab consolidation therapy.
    Brugger W
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):33-7. PubMed ID: 15042533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation.
    Klener P; Salek D; Pytlik R; Mocikova H; Forsterova K; Blahovcova P; Campr V; Prochazka V; Obr A; Jaksa R; Kuntscherova J; Boudová L; Kodet R; Janikova A; Trneny M
    Am J Hematol; 2019 Feb; 94(2):E50-E53. PubMed ID: 30474171
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of older patients with mantle-cell lymphoma.
    Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH
    N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-Line Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: A Systematic Analysis and Treatment Recommendation.
    Liu H; Shi X; Fang H; Cao L; Miao Y; Zhao X; Wu W; Xu W; Li J; Fan L
    Front Oncol; 2022; 12():881346. PubMed ID: 35646653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
    Visco C; Chiappella A; Nassi L; Patti C; Ferrero S; Barbero D; Evangelista A; Spina M; Molinari A; Rigacci L; Tani M; Rocco AD; Pinotti G; Fabbri A; Zambello R; Finotto S; Gotti M; Carella AM; Salvi F; Pileri SA; Ladetto M; Ciccone G; Gaidano G; Ruggeri M; Martelli M; Vitolo U
    Lancet Haematol; 2017 Jan; 4(1):e15-e23. PubMed ID: 27927586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era.
    Mussetti A; Devlin SM; Castro-Malaspina HR; Barker JN; Giralt SA; Zelenetz AD; Sauter CS; Perales MA
    Bone Marrow Transplant; 2015 Oct; 50(10):1293-1298. PubMed ID: 26146802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial.
    Pettengell R; Uddin R; Boumendil A; Johnson R; Metzner B; Martín A; Romejko-Jarosinska J; Bence-Bruckler I; Giri P; Niemann CU; Robinson SP; Kimby E; Schmitz N; Dreger P; Goldstone AH; Montoto S
    Bone Marrow Transplant; 2021 Jun; 56(6):1413-1421. PubMed ID: 33452448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.